SPY423.11+2.25 0.53%
DIA339.45+0.67 0.20%
IXIC14,253.27+111.79 0.79%

BRIEF-Innate Pharma Q1 Revenues Down At EUR 4.5 Mln

05/11/2021 01:08
BRIEF-Innate Pharma Q1 Revenues Down At EUR 4.5 Mln

- INNATE PHARMA SA IPH.PA:

  • CASH POSITION OF EUR 181.7 MILLION¹ AS OF MARCH 31, 2021

  • LACUTAMAB TELLOMAK TRIAL PROGRESSES AS KIR3DL2-EXPRESSING MYCOSIS FUNGOIDES COHORT ADVANCES TO STAGE 2 AFTER POSITIVE EARLY SIGNAL

  • COMPANY'S FIRST NK CELL ENGAGER SELECTED BY SANOFI AS DRUG CANDIDATE FOR DEVELOPMENT

  • REVENUES FOR FIRST THREE MONTHS OF 2021 AMOUNTED TO EUR 4.5 MILLION (EUR 19.3 MILLION FOR SAME PERIOD IN 2020)

Source text for Eikon: ID:nGNX25ZNgR

Further company coverage: IPH.PA


(Gdansk Newsroom)

(([email protected]uters.com; +48 58 778 51 10;))